Latest:
EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S Mutation
Expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Sameer A. Parikh, MBBS
Latest:
Recognizing BTKi Resistance in CLL—Incorporating Pirtobrutinib in Relapsed/Refractory Disease
Panelists discuss how Bruton tyrosine kinase (BTK) resistance mutation testing is routinely performed at disease progression, but currently doesn’t change treatment decisions because pirtobrutinib shows comparable efficacy regardless of mutation status. However, high-level mutations (C481S or L528W) might favor venetoclax-based therapy over pirtobrutinib in second-line treatment. The panelists also emphasize the importance of patient education; approximately one-third of progressive patients lack detectable resistance mutations yet still require treatment changes based on clinical progression rather than molecular findings.
David Miklos, MD
Latest:
Future Perspectives for the Treatment of Relapsed/Refractory DLBCL
A reflection on key accomplishments in DLBCL treatment, highlighting pivotal developments that have shaped clinical practice, followed by a look ahead to 2025, focusing on areas poised for significant progress and personal goals for the coming year
Lauren Shaff, MD
Lauren Shaff, MD, is a neuro-oncologist and associate director of the Neuro-Oncology Fellowship Program at Memorial Sloan Kettering Cancer Center.
Latest:
Dr Schaff on a Phase 1 Study of Copanlisib Plus Ibrutinib in Relapsed/Refractory PCNSL
Lauren Shaff, MD, contextualizes results from a phase 1 study evaluating copanlisib plus ibrutinib in relapsed/refractory primary and secondary CNS lymphoma.
Juan Carlos Hernández-Boluda, MD, PhD
Juan Carlos Hernández-Boluda, MD, PhD, is an associated physician at the Hematology and Medical Oncology Service of the Hospital Clínico of Valencia
Latest:
Dr Hernández-Boluda on Machine Learning for Identifying Transplant Risk in Myelofibrosis
Juan Carlos Hernández-Boluda, MD, PhD, details the advantages of EBMT machine learning vs existing transplant risk assessment tools in myelofibrosis.
Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd
Tarek M. Mekhail, MD, MSc, FRCSI, FRCSEd, is the medical director of the Thoracic Cancer Program, and associate executive director at AdventHealth Cancer Institute.
Latest:
Lung Cancer Experts Highlight the Significance and Limitations of ADCs
Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.
Yardlee Kauffman, PharmD, MPH
Latest:
A New Generation of Cytokine-Based Immunotherapy Takes Shape
Nearly 40 years after the first cytokine-based therapy was approved for the treatment of patients with hairy cell leukemia, investigators are taking a fresh look at ways to leverage these signaling proteins to enhance immunotherapies and vaccines in other cancers.
Jeffery Auletta, MD
Jeffery Auletta, MD, is a blood and marrow transplant physician at Nationwide Children’s Hospital.
Latest:
Drs Al Malki and Auletta on PTCy GVHD Prophylaxis in Patients With HLA-UUMD
Monzr Al Malki, MD and Jeffery J. Auletta, MD discuss evaluating PTCy-based GVHD prophylaxis in hematologic malignancies.
Suyash Mohan, MD
Latest:
Monitoring DMG Treatment Response Using RANO 2.0 Criteria
Experts discuss the evolution of the Response Assessment in Neuro-Oncology (RANO) criteria culminating in RANO 2.0, which standardizes treatment response evaluation for gliomas by refining imaging benchmarks, simplifying measurement methods, and addressing challenges in distinguishing progression from treatment effects to enhance consistency in both clinical trials and routine practice.
